0.9601
Imunon Inc Borsa (IMNN) Ultime notizie
DNA Vaccines Offer a New Path Beyond mRNA Technology - Technology Networks
Stacy Lindborg, PhD's Profile Page - Technology Networks
Companies To Watch: Imunon - Life Science Leader
IMNN: Protocol in Place for Phase 3 Trial of IMNN-001 in Ovarian Cancer - Smartkarma
IMNN: Protocol in Place for Phase 3 Trial of IMNN-001 in Ovarian Cancer… - Zacks Small Cap Research
Imunon (NASDAQ:IMNN) Earns “Buy” Rating from HC Wainwright - Defense World
FDA aligns with Imunon’s Phase III trial protocol for ovarian cancer treatment - Yahoo
Imunon (NASDAQ:IMNN) Receives “Buy” Rating from D. Boral Capital - Defense World
IMUNON advances to Phase 3 trial in ovarian cancer treatment By Investing.com - Investing.com South Africa
Imunon finalizes Phase 3 study design with FDA for IMNN-001 - TipRanks
IMUNON advances to Phase 3 trial in ovarian cancer treatment - Investing.com India
IMUNON Finalizes Phase 3 Study Design with FDA for IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer - GlobeNewswire
Breakthrough Ovarian Cancer Treatment Shows 46-Month Survival as FDA Clears Phase 3 Trial - Stock Titan
IMUNON’s IMNN-101 Vaccine Shows Promising Results in Phase 1 Trial, Demonstrates Cross-Reactivity Against COVID Variants - Contagionlive.com
Imunon, Inc. Earnings Call: Clinical Success Amid Financial Challenges - TipRanks
Imunon’s (IMNN) “Buy” Rating Reiterated at D. Boral Capital - Defense World
Imunon’s Strategic Clinical Advancements and Promising Research Drive Buy Rating - TipRanks
Imunon, Inc. (NASDAQ:IMNN) Q4 2024 Earnings Call Transcript - Insider Monkey
H.C. Wainwright lifts Imunon stock target to $14 on Phase 3 plans By Investing.com - Investing.com South Africa
H.C. Wainwright lifts Imunon stock target to $14 on Phase 3 plans - Investing.com
Imunon Inc (IMNN) Q4 2024 Earnings Call Highlights: Promising Advances Amid Financial Challenges - Yahoo Finance
IMUNON, Inc. Reports 2024 Financial Results and Advances Clinical Programs - TipRanks
Earnings call transcript: Imunon Q4 2024 reports improved EPS, stock declines - Investing.com
Imunon Inc reports results for the quarter ended December 31Earnings Summary - TradingView
IMUNON Reports 2024 Financial Results and Provides Business Update - TradingView
IMUNON Reports 2024 Financial Results and Provides Business - GlobeNewswire
IMUNON's Cancer Immunotherapy Shows 13-Month Survival Benefit in Ovarian Cancer | IMNN Stock News - StockTitan
Imunon reports immunogenicity and safety data from DNA plasmid vaccine trial - Yahoo Finance
Imunon announces new analyses of results from Phase 1 trial of IMNN-101 - TipRanks
IMUNON Announces New Immunogenicity Data from Phase 1 - GlobeNewswire
Can IMUNON's DNA Vaccine Outperform mRNA COVID Shots? New Clinical Data Reveals Key Advantages - StockTitan
Imunon (IMNN) Expected to Announce Quarterly Earnings on Thursday - Defense World
Imunon Inc [IMNN] Shares Jump Approximately 66.98% Over the Year - Knox Daily
The time has not yet come to remove your chips from the table: Imunon Inc (IMNN) - SETE News
IMUNON to Hold 2024 Financial Results and Business Update Conference Call on Thursday, February 27, 2025 - The Manila Times
IMUNON, Inc. to Announce Full Year 2024 Financial Results on February 27, 2025 - Nasdaq
New Phase II data confirm promise of Imunon’s IMMN-001 - The Pharma Letter
IMUNON Announces Translational Data from Phase 1/2 OVATION 2 Study of IMNN-001 in Advanced Ovarian Cancer - GlobeNewswire
Imunon Announces Translational Data From Phase 1/2 Ovation 2 Study Of Imnn-001 In Advanced Ovarian Cancer - Marketscreener.com
Ovarian Cancer Breakthrough? New Drug Shows 13-Month Survival Advantage in Clinical Trial - StockTitan
IMUNON names Douglas Faller as chief medical officer - MSN
IMUNON Appoints Douglas V. Faller, M.D., Ph.D., as Chief Medical Officer - GlobeNewswire
Imunon names industry vet Douglas Faller as CMO - The Pharma Letter
Imunon Appoints Dr. Douglas Faller as CMO - TipRanks
Imunon director Donald Braun acquires $29,480 worth of shares - MSN
Analyzing Imunon (NASDAQ:IMNN) & Unicycive Therapeutics (NASDAQ:UNCY) - Defense World
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):